Methods for preventing fibrosis using cxcr4 and/or cxcr7 binding agents
AssigneesViCapsys.Inc, The General Hospital Corporation
InventorsMark Poznansky, James Markmann, Timothy Brauns, Marinko Sremac, Nicolas Chronos, Suren Chavan
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to methods of treating a subject with a fibrotic or fibroproliferative disease, comprising administering to the subject a composition comprising an effective amount of an anti-fibrosis agent, e.g., a CXCR4 and/or CXCR7 binding agent, such as CXCL12.
Claims27
A method for preventing or attenuating fibrosis and/or adhesion formation in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition comprising a CXCR4 and/or CXCR7 binding agent, thereby preventing or attenuating fibrosis and/or adhesion formation.
A method for preventing or attenuating scarring in a subject in need thereof, the method comprising administering to the subject a composition comprising an effective amount of a CXCR4 and/or CXCR7 binding agent to a site of potential scarring, thereby preventing or attenuating scarring.
18-22. (canceled)
A method for treating, preventing, or inhibiting progression of a fibrotic disease in a subject in need thereof, the method comprising administering to the subject a composition comprising an effective amount of a CXCR4 and/or CXCR7 binding agent to the site of fibrosis, thereby treating, preventing, or inhibiting progression of the fibrotic disease.
(canceled)
27-28. (canceled)
(canceled)
32-44. (canceled)
Dependencies are inferred from the claim text.